# Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）

Source: https://onco.cc/trials/nct05429463/  
OnCo record `nct05429463` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of sintilimab, carboplatin and nab-paclitaxel in lung cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.

## Summary

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II） is a phase 3, randomised interventional study registered as NCT05429463 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 250 participants, started 2022-11-11 and due to reach its primary completion in 2025-11-11. Interventions recorded: Sintilimab; Carboplatin; Albumin-Bound Paclitaxel. Conditions listed: Squamous Cell Non-small Cell Lung Cancer. Primary outcome: Major pathological response rate (MPR). Lung eligibility wording from the registry: "Squamous Cell Non-small cell lung cancer confirmed by cytology or histology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: neoSCORE II
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05429463
- Phase: 3
- Setting: Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE II）：A Prospective, Randomized, Open-Label, Multi-Center Phase 3 Trial
- Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT05429463: https://clinicaltrials.gov/study/NCT05429463

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05429463.json